5. The patient received Imatinib mesylate, a drug that has demonstrated its utility for metastasizing lesions. This could eventually improve the long term prognosis for this case because this tumor presented a medium risk of progression according to pathology, Fletcher classification and presence of bleeding.
5. Se administró Mesilato de Imatinib, medicamento que ha demostrado utilidad en enfermedad metastásica, lo que podría eventualmente mejorar el pronóstico a largo plazo de este caso, ya que por patología, clasificación fletcher y presencia de sangrado presenta riesgo intermedio.